Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Coherus Oncology's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was €18.19 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was €79.58 Mil.
Coherus Oncology (FRA:8C5) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Coherus Oncology Selling, General, & Admin. Expense Related Terms
Coherus Oncology Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology Selling, General, & Admin. Expense Chart
FRA:8C5 vs NAUT, AVXL, SLNCF: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, Coherus Oncology's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Selling, General, & Admin. Expense falls into.
Coherus Oncology Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €79.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of €79.58 Mil mean?
Coherus Oncology (FRA:8C5) has a Selling, General, & Admin. Expense of €79.58 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Coherus Oncology and its competitors.
Is Coherus Oncology's Selling, General, & Admin. Expense too high?
Coherus Oncology's current Selling, General, & Admin. Expense is €79.58 Mil. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Selling, General, & Admin. Expense compare to NAUT and AVXL?
Coherus Oncology's Selling, General, & Admin. Expense of €79.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Selling, General, & Admin. Expense is €79.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.27 — trading 84.5% above its estimated fair value. The current Selling, General, & Admin. Expense is €79.58 Mil. Coherus Oncology's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Selling, General, & Admin. Expense is €79.58 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.27 is trading 84.5% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Selling, General, & Admin. Expense: €79.58 Mil
GF Value™: €0.69 vs. price of €1.27 (84.5% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score
Get the complete analysis for FRA:8C5
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
